Parc Biocitech, Romainville, June 8, 2009 - the genome engineering company Cellectis S.A. (Alternext: ALCLS) today announced the initiation of coverage by Natixis Midcaps Research.  Research on the Company is now available through four investment banks:  Société Générale (Rodolphe Besserve), NexResearch (Ali Dhaloomal), Invest Securities (Daniel Anizon) and Natixis Securities (Sylvain Goyon).  Information on these reports can be obtained by contacting the banks directly.